FDA Launches Postmarket Chemical Review Program to Ensure Food Safety
By Stephanie Brown HealthDay Reporter
MONDAY, May 19, 2025 -- Last week, the U.S. Food and Drug Administration announced a move to improve transparency and strengthen the safety of chemicals used in the nation's food supply.
The agency is implementing an enhanced review process for food chemicals currently available on the U.S. market, with a particular focus on those that have raised consumer concerns.
Previously, the FDA conducted postmarket reviews reactively, typically triggered by citizen petitions or emerging scientific evidence. Now, the agency is implementing a new framework for these reviews. This updated approach will be "proactive, science-based, and built for long-term impact," the FDA writes in a press release.
"We are prioritizing our resources and leveraging gold standard science to create, for the first time, a systematic postmarket review program that consumers can trust and rely on," FDA Commissioner Martin A. Makary, M.D., M.P.H., said in a statement. "Only by improving the safety and transparency of the food supply and ensuring consumers can make healthful food choices will we overcome the long-standing trajectory of chronic diseases."
During the next few months, the FDA is planning to implement several key actions, including a new, evidence-based approach to prioritizing the review of existing chemicals, with a draft of this scheme to be released soon for public feedback. Additionally, the FDA will be implementing a final, systematic process for postmarket review, which has been developed with input from stakeholders.
The FDA will also update its list of chemicals currently under review, including synthetic antioxidant food additives butylated hydroxyanisole, butylated hydroxytoluene, and azodicarbonamide, a chemical foaming agent. The agency intends to expedite the review process for chemicals already under scrutiny, such as phthalates, propylparaben, and titanium dioxide.
As part of its commitment to greater transparency, the FDA will continue to provide updates on the progress of this work on its website.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-20 06:00
Read more

- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer
- Common Diabetes Drug, Metformin, Effective Against Knee Arthritis Pain
- Psilocybin Use Dramatically Increasing In U.S.
- FDA Gives Marketing Nod to Blood Test for Diagnosing Alzheimer Disease
- USDA Drops Plan to Limit Salmonella in Poultry Products
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions